PetMed Express, Inc. (NASDAQ:PETS) – Analysts at Northcoast Research raised their Q3 2018 earnings per share (EPS) estimates for shares of PetMed Express in a note issued to investors on Monday. Northcoast Research analyst E. Snyder now expects that the company will post earnings of $0.30 per share for the quarter, up from their prior estimate of $0.29. Northcoast Research has a “Buy” rating and a $54.00 price objective on the stock. Northcoast Research also issued estimates for PetMed Express’ Q4 2018 earnings at $0.39 EPS and Q1 2019 earnings at $0.48 EPS.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Monday, October 23rd. The company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.30 by $0.13. PetMed Express had a net margin of 10.34% and a return on equity of 28.67%. The business had revenue of $66.70 million during the quarter, compared to the consensus estimate of $63.41 million. During the same quarter last year, the company posted $0.24 earnings per share. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year.

COPYRIGHT VIOLATION WARNING: “PetMed Express, Inc. Expected to Earn Q3 2018 Earnings of $0.30 Per Share (PETS)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/24/petmed-express-inc-expected-to-earn-q3-2018-earnings-of-0-30-per-share-pets.html.

Several other research firms have also commented on PETS. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a research report on Wednesday, July 26th. Craig Hallum reiterated a “hold” rating and set a $40.00 price objective (down from $43.00) on shares of PetMed Express in a research note on Monday, August 21st. They noted that the move was a valuation call. BidaskClub downgraded PetMed Express from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 22nd. Sidoti upgraded PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Thursday, August 24th. Finally, ValuEngine upgraded PetMed Express from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $40.00.

PetMed Express (NASDAQ PETS) traded down 12.35% during mid-day trading on Tuesday, reaching $38.05. 1,469,605 shares of the company were exchanged. PetMed Express has a one year low of $18.90 and a one year high of $50.90. The company has a market capitalization of $772.11 million, a PE ratio of 29.27 and a beta of 1.03. The stock has a 50-day moving average price of $35.86 and a 200 day moving average price of $36.30.

In related news, Director Ronald J. Korn sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $48.18, for a total transaction of $240,900.00. Following the completion of the transaction, the director now directly owns 67,333 shares in the company, valued at approximately $3,244,103.94. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Bruce S. Rosenbloom sold 6,833 shares of the business’s stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $50.18, for a total value of $342,879.94. Following the transaction, the chief financial officer now owns 18,534 shares of the company’s stock, valued at $930,036.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,333 shares of company stock valued at $949,730. 4.00% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the stock. Pinebridge Investments L.P. grew its stake in shares of PetMed Express by 1.0% during the 2nd quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after acquiring an additional 27 shares during the period. Arizona State Retirement System grew its stake in shares of PetMed Express by 0.9% during the 1st quarter. Arizona State Retirement System now owns 10,667 shares of the company’s stock valued at $215,000 after acquiring an additional 100 shares during the period. Texas Permanent School Fund grew its stake in shares of PetMed Express by 0.8% during the 2nd quarter. Texas Permanent School Fund now owns 14,986 shares of the company’s stock valued at $608,000 after acquiring an additional 125 shares during the period. Advisor Group Inc. grew its stake in shares of PetMed Express by 0.7% during the 2nd quarter. Advisor Group Inc. now owns 24,844 shares of the company’s stock valued at $1,009,000 after acquiring an additional 179 shares during the period. Finally, QS Investors LLC grew its stake in shares of PetMed Express by 4.0% during the 2nd quarter. QS Investors LLC now owns 9,324 shares of the company’s stock valued at $379,000 after acquiring an additional 356 shares during the period. Institutional investors own 81.09% of the company’s stock.

PetMed Express Company Profile

PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.

Earnings History and Estimates for PetMed Express (NASDAQ:PETS)

Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.